TalkMed Group Beheer

Beheer criteriumcontroles 2/4

De CEO TalkMed Group is Peng Tiam Ang, benoemd in Sep2013, heeft een ambtstermijn van 11.17 jaar. bezit rechtstreeks 64.69% van de aandelen van het bedrijf, ter waarde SGD 377.92M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 10.2 jaar en 3.1 jaar.

Belangrijke informatie

Peng Tiam Ang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	11.2yrs
Eigendom CEO	64.7%
Management gemiddelde ambtstermijn	10.2yrs
Gemiddelde ambtstermijn bestuur	3.1yrs

Recente managementupdates

Recent updates

TalkMed Group (SGX:5G3) Seems To Use Debt Quite Sensibly

Sep 26

Unpleasant Surprises Could Be In Store For TalkMed Group Limited's (SGX:5G3) Shares

Apr 08

TalkMed Group's (SGX:5G3) Solid Earnings Have Been Accounted For Conservatively

Mar 01

CEO

Peng Tiam Ang (65 yo)

11.2yrs

Tenure

Dr. Peng Tiam Ang has been the Chief Executive Officer of TalkMed Group Limited since September 10, 2013. Dr. Ang provides the vision and the strategic direction for TalkMed Group. He serves as Medical Dir...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peng Tiam Ang	CEO & Executive Director	11.2yrs	geen gegevens	64.69% SGD 377.9m
Boon Yong Lee	Group CFO & Joint Company Secretary	10.2yrs	geen gegevens	geen gegevens
Kei Siong Khoo	Chief Operating Officer	11.2yrs	geen gegevens	7.48% SGD 43.7m
Heng Chong Lim	Joint Company Secretary	9.1yrs	geen gegevens	geen gegevens
Jacqueline Anne Low	Joint Company Secretary	3.2yrs	geen gegevens	geen gegevens

10.2yrs

Gemiddelde duur

Ervaren management: Het managementteam van 5G3 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 10.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peng Tiam Ang	CEO & Executive Director	11.2yrs	geen gegevens	64.69% SGD 377.9m
Kei Siong Khoo	Chief Operating Officer	no data	geen gegevens	7.48% SGD 43.7m
Yih Pin Sitoh	Non-Independent Non-Executive Director	10.9yrs	geen gegevens	geen gegevens
S. Chandra Rajagopal Sitaram Das	Non-Independent Non-Executive Chairman	10.9yrs	geen gegevens	0.083% SGD 484.2k
Swee Yam Sim	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Ching Ching Leong	Independent Non-Executive Director	3.1yrs	geen gegevens	0.023% SGD 132.0k
Khai Tong Tan	Independent Non-Executive Director	less than a year	geen gegevens	0.0045% SGD 26.4k
Kok Shang Lam	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens

3.1yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 5G3 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).

TalkMed Group Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

TalkMed Group Limited, Annual General Meeting, Apr 18, 2024

TalkMed Group Limited Announces Management Changes

TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

TalkMed Group (SGX:5G3) Seems To Use Debt Quite Sensibly

Upcoming dividend of S$0.023 per share

First half 2024 earnings released: EPS: S$0.006 (vs S$0.009 in 1H 2023)

First half dividend of S$0.023 announced

Upcoming dividend of S$0.013 per share

TalkMed Group Limited Approves Final One-Tier Tax-Exempt Dividend for the Financial Year Ended 31 December 2023

Unpleasant Surprises Could Be In Store For TalkMed Group Limited's (SGX:5G3) Shares

Final dividend reduced to S$0.013

TalkMed Group Limited, Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released

Talkmed Group Limited Proposes Tax Exempt (One-Tier) Final Dividend for the Financial Year Ended 31 December 2023, Payable on 10 May 2024

TalkMed Group Limited Announces Management Changes

TalkMed Group Limited Appoints Lam Kok Shang as Independent Non-Executive Director, Chairman of the Audit and Risk Committee, Member of the Nominating Committee, Effective January 1, 2024

First half 2023 earnings released: EPS: S$0.011 (vs S$0.009 in 1H 2022)

TalkMed Group Limited Approves the Final One-Tier Tax-Exempt Dividend in Respect of 2022

Upcoming dividend of S$0.015 per share at 7.0% yield

Full year 2022 earnings released: EPS: S$0.023 (vs S$0.019 in FY 2021)

TalkMed Group's (SGX:5G3) Solid Earnings Have Been Accounted For Conservatively

Full year 2022 earnings released

Insufficient new directors

TalkMed Group Limited Announces Tax Exempt (One-Tier) Interim Cash Dividend, Payable on 22 August 2022

First half 2022 earnings released

Insufficient new directors

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

TalkMed Group Limited, Annual General Meeting, Apr 21, 2022

Insufficient new directors

Full year 2021 earnings: Revenues exceed analyst expectations

TalkMed Group Limited Proposes Final Dividend, Payable on 11 May 2022

Joint Company Secretary Lingna Dai has left the company

New 90-day low: S$0.40

TalkMed Group Limited, Annual General Meeting, Apr 20, 2021

Full year 2020 earnings released

Revenue beats expectations, earnings disappoint

New 90-day high: S$0.46

New 90-day low: S$0.38

First half earnings released

New 90-day low - S$0.38

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd